We are live on ! Find out more
PLRX icon

Pliant Therapeutics
PLRX

55 hedge funds and large institutions have $635M invested in Pliant Therapeutics in 2020 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

164% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 11

49% more funds holding

Funds holding: 37 → 55 (+18)

0.14% less ownership

Funds ownership: 79.7% → 79.56% (-0.14%)

22% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 9

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

28% less capital invested

Capital invested by funds: $877M → $635M (-$242M)

Holders
55
Holders Change
+18
Holders Change %
+48.65%
% of All Funds
1.11%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.06%
New
29
Increased
7
Reduced
9
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$10.4M
2
BlackRock
BlackRock
New York
+$9.97M
3
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$4.84M
4
WP
Woodline Partners
California
+$3.8M
5
Northern Trust
Northern Trust
Illinois
+$3.03M

Top Sellers

1
LGM
Logos Global Management
California
-$7.99M
2
SCM
Suvretta Capital Management
New York
-$3.07M
3
ZP
Zimmer Partners
New York
-$2.78M
4
PAMU
Pictet Asset Management (UK)
United Kingdom
-$2.6M
5
FCM
Farallon Capital Management
California
-$2.16M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
51
Citigroup
New York
$11K +$12.5K +500 New
CAW
52
Cornerstone Advisors (Washington)
Washington
$1K +$1.05K +42 New
Millennium Management
53
Millennium Management
New York
$388 -$1.32M -52,920 -76%
SCM
54
Suvretta Capital Management
New York
– -$3.07M -94,700 Closed
ZP
55
Zimmer Partners
New York
– -$2.78M -85,741 Closed
PAMU
56
Pictet Asset Management (UK)
United Kingdom
– -$2.6M -80,000 Closed
Goldman Sachs
57
Goldman Sachs
New York
– -$1.46M -45,000 Closed
MWNA
58
Marshall Wace North America
New York
– -$1.26M -38,825 Closed
MIM
59
Monashee Investment Management
Massachusetts
– -$1.17M -36,000 Closed
DKCM
60
Davidson Kempner Capital Management
New York
– -$772K -24,000 Closed
Jane Street
61
Jane Street
New York
– -$435K -13,389 Closed
MS
62
Maven Securities
Jersey
– -$253K -7,800 Closed
EC
63
EcoR1 Capital
California
– -$42K -1,300 Closed
PCM
64
Pinz Capital Management
New York
– -$16K -500 Closed
NFG
65
Next Financial Group
Texas
– +$500 +20 New
TWA
66
TCI Wealth Advisors
Arizona
– +$525 +21 New
1 2
3

PLRX Hedge Fund Activity: Q3 2020 in Review

55 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q3 2020, worth a combined $635M — down 28% from $877M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new PLRX positions and 11 closed out — a net gain of 18 holders — while 7 added to existing stakes and 9 trimmed.

The largest buyer was Vanguard Group, adding an estimated $10.4M. The largest seller was Logos Global Management, cutting an estimated $7.99M.

  • 55 institutional investors held Pliant Therapeutics (PLRX) as of Q3 2020, up from 37 in Q2 2020.
  • Funds reported $635M of Pliant Therapeutics stock for Q3 2020, down 28% quarter-over-quarter.
  • 29 funds opened new Pliant Therapeutics positions in Q3 2020 and 11 closed out, a net change of +18 holders.
  • The largest Pliant Therapeutics buyer in Q3 2020 was Vanguard Group, an estimated $10.4M added.
  • The largest Pliant Therapeutics seller in Q3 2020 was Logos Global Management, an estimated $7.99M sold.

Based on aggregated 13F filings for Q3 2020.